Predictive Value of Nuclear Excision Repair Genes for Cancer Survival

Patients who have their cancer surgically removed are at risk for recurrence, even though currently free of disease. Lung cancer patients with higher activity of a nuclear excision repair gene called ERCC1 were at a lower risk for recurrence than patients with lower activity of ERCC1. Hence, it is possible to predict which patients are at a higher risk for recurrence after resection. This information can be used to design treatment strategies for patients determined to be at a higher risk for recurrence. Additionally, patients who are lower risk for recurrence can be saved the morbidity of further treatment.

Patents:
US 20,110,143,361

Inventor(s): SIMON GEORGE R [US]; BEPLER GEROLD [US]

Type of Offer: Licensing



« More Biotech Patents
« More Genetics Patents

---